Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction

Coronary Artery Disease

Volumn 23, Issue 7, 2012, Pages 460-468

  Xiao, Jian ^a   Li, Bingong ^b   Zheng, Zeqi ^b   Wang, Menghong ^b   Peng, Jingtian ^b   Li, Yong ^a   Li, Zhe ^a  

^a Hypertensive Research Institute   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

angiogenesis; apoptosis; cardiac function; gene transduction; neuregulin 1

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEU DIFFERENTIATION FACTOR; PROTEIN BAX; PROTEIN KINASE B;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HEART FUNCTION; HEART INFARCTION; LENTIVIRINAE; MICROVASCULATURE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IN SITU NICK-END LABELING; LENTIVIRUS; MICROFILAMENT PROTEINS; MICROVESSELS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; NERVE TISSUE PROTEINS; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECOVERY OF FUNCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROKE VOLUME; TIME FACTORS; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84867579183     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32835877da     Document Type: Article

References (42)

1. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2635.
2. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101:2981-2988.
3. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cell. Circulation 2011; 15:100-112.
4. Fischer KM, Cottage CT, Wu W, Din S, Gude NA, Avitabile D, et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 2009; 120:2077-2087.
5. Khan M, Meduru S, Gogna R, Madan E, Citro L, Kuppusamy ML, et al. Oxygen cycling in conjunction with stem cell transplantation induces NOS3 expression leading to attenuation of fibrosis and improved cardiac function. Cardiovasc Res 2012; 93:89-99.
6. Li B, Zeng Q, Wang H, Shao S, Mao X, Zhang F, et al. Adipose tissue stromal cells transplantation in rats of acute myocardial infarction. Coron Artery Dis 2007; 18:221-227.
7. Li B, Zheng Z,Wei Y,Wang M, Peng J, Kang T, et al. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol 2011; 29:69.
8. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378:386-390.
9. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor ErbB2 in neural and cardiac development. Nature 1995; 378:394-398.
10. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378:390-394.
11. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hü bner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 2002; 99:8880-8885.
12. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanism into preventative medicine. Mol Interv 2005; 5:163-171.
13. Lemmens K, Segers VF, Demolder M, De Keulenaer GW. Role of neuregulin- 1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 2006; 281:19469-19477.
14. Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, Sawyer DB. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/ErbB4 signaling. J Biol Chem 2004; 279:51141-51147.
15. Liu X, Gu X, Li Z, Li H, Chang J, Chen P, et al. Neuregulin-1/ErbB- activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006; 48:1438-1447.
16. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 8:e1000412.
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
18. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity. Circulation 2000; 102:272-274.
19. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273:10261-10269.
20. Baliga RR, Pimental DR, Zhao YY, Simmons WW, Marchionni MA, Sawyer DB, Kelly RA. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3- kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol 1999; 277: H2026-H2037.
21. Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via ErbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 2003; 35:1473-1479.
22. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates ErbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006; 41:228-235.
23. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-ErbB2: Potential mechanism for trastuzumabinduced cardiotoxicity. Circulation 2002; 105:1551-1554.
24. Hertig CM, Kubalak SW,Wang Y, Chien KR. Synergistic roles of neuregulin- 1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis. J Biol Chem 1999; 274:37362-37369.
25. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009; 120:310-317.
26. Calvo M, Zhu N, Grist H, Ma Z, Loeb JA, Bennett DL. Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway. Glia 2011; 59:554-568.
27. Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebocontrolled study of the efficacy and safety of recombinant human neuregulin- 1 in patients with chronic heart failure. J Am Coll Cardiol 2010; 55: 1907-1914.
28. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 2011; 13:83-92.
29. Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB. Neuregulin-1 alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 2005; 311:135-146.
30. Lemmens K, Fransen P, Sys SU, Brutsaert DL, De Keulenaer GW. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: Role of nitric oxide synthase. Circulation 2004; 109:324-326.
31. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399:597-601.
32. Zhao X, Lu X, Feng Q. Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol 2002; 283:H2371-H2378.
33. Xu Z, Park SS, Mueller RA, Bagnell RC, Patterson C, Boysen PG. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res 2005; 65:803-812.
34. Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 2006; 72: 152-162.
35. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemiareperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002; 105:1497-1502.
36. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: The role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003; 35:185-193.
37. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
38. Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp Cell Res 2007; 313: 1588-6011.
39. Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, Russell KS. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 2011; 123:2254-2262.
40. Gu X, Liu X, Xu D, Li X, Yan M, Qi Y, et al. Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. Cardiovasc Res 2010; 88:334-343.
41. Brero A, Ramella R, Fitou A, Dati C, Alloatti G, Gallo MP, Levi R. Neuregulin- 1 beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res 2010; 88:443-452.
42. Annageisberg C,Wang G, Safa RN, Smith HM, Anderson B, Peng XY, et al. Circulating neuregulin-1b levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis 2011; 22: 577-582.